Home/Pipeline/CUR-003

CUR-003

Inflammatory Disease

PreclinicalLead Optimization

Key Facts

Indication

Inflammatory Disease

Phase

Preclinical

Status

Lead Optimization

Company

Curatis

About Curatis

Curatis is a Swiss public biotech focused on developing innovative therapeutics for rare diseases and oncology. Its core asset is a proprietary technology platform designed to identify novel targets and generate optimized drug candidates. The company's strategy centers on advancing its clinical-stage programs, CUR-001 and CUR-002, through proof-of-concept while expanding its preclinical pipeline. With a modest market valuation, Curatis represents a high-risk, high-reward investment opportunity in the specialized European biotech sector.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders

Other Inflammatory Disease Drugs

Drug	Company	Phase	Status
RIPK2 inhibitor	Acellera	Pre-clinical	Hit-to-Lead
Undisclosed PPI Program	Perha Pharmaceuticals	Preclinical	Active
AKST4290	Alkahest	Research	Active
STX-0812	Solu Therapeutics	Preclinical	Active